1. Introduction

Digital Immortality Biotechnology Regulation is an emerging field of legal and ethical governance concerned with the use of biotechnology, genetic engineering, artificial intelligence, regenerative medicine, cellular reprogramming, cryopreservation and neurotechnology to extend human life, preserve biological identity, or potentially reconstruct aspects of an individual's identity beyond their natural lifespan.

The concept of digital immortality intersects two different technological developments:

Biological immortality: Scientific attempts to delay ageing, regenerate damaged organs, preserve cells and tissues, modify genetic processes, and extend human lifespan.

Digital immortality: Preservation or reconstruction of a person's memories, personality, behavioural patterns, genetic information, voice, appearance and digital identity through computational systems.

Their convergence creates complex legal questions:

Can biotechnology companies legally experiment with technologies intended to extend human life?

Who owns a person's genetic information and preserved biological materials?

Can a deceased person's digital personality continue to operate through AI?

Can a person consent in advance to cryogenic preservation or posthumous biological experimentation?

Who bears responsibility when experimental longevity treatments cause injury or death?

Can genetic modification be used to create inheritable changes intended to prevent ageing?

Should a digitally reconstructed person possess any legal rights?

Central legal proposition: Human longevity and digital continuity must remain subject to human dignity, informed consent, bodily autonomy, scientific accountability, privacy, equality and public-interest regulation.

There is currently no universally recognised independent legal doctrine called the Digital Immortality Biotechnology Regulation Doctrine. It is an emerging interdisciplinary framework developed by applying existing biotechnology, medical, constitutional, intellectual-property, data-protection and AI laws.

2. Meaning and Scope of Digital Immortality Biotechnology Regulation

The proposed regulatory framework encompasses the following technologies.

A. Genetic engineering and anti-ageing biotechnology

Harnessing CRISPR: A Comprehensive Guide for Future Physi...

Fibroblast-derived iPSC Reprogramming Workflow | BioRender Science Templates

Breakthrough could impact cancer, ageing and heart disease

7

These technologies seek to understand or modify biological mechanisms associated with ageing.

Examples include:

CRISPR-based genetic modification.

Telomere-length regulation.

Cellular reprogramming.

Stem-cell-based regenerative therapies.

Senescence-targeting treatments.

Mitochondrial interventions.

Tissue and organ regeneration.

Legal concern: Genetic modification must be distinguished between permissible somatic treatment and potentially inheritable germline modification. The latter raises additional concerns involving future generations, consent and intergenerational harm.

B. Cryonics and biological preservation

Come funziona una biobanca | Wired Italia

Aufbewahrungsbehälter & Einfriergeräte | Linde Gas Schweiz

Bioethik-Kommission pocht auf Selbstbestimmung - TV Mittelrhein

10

Cryonics involves preserving a human body or parts of it at extremely low temperatures in the hope that future scientific developments might permit restoration.

Relevant legal questions include:

Whether cryopreservation constitutes medical treatment, research or posthumous disposition.

Whether a person can legally provide advance consent.

Whether family members can challenge preservation arrangements.

Whether biological material can be transferred between preservation providers.

Whether misleading claims about future revival constitute consumer fraud.

Importantly, cryopreservation of a legally deceased person does not currently establish a scientifically demonstrated method of restoring that person to life.

C. Digital personality preservation

Online Memorial Communication and the New Rules of Grieving

theirvoice.ai

AI systems may use recorded conversations, photographs, videos, genetic information and behavioural records to create digital representations of deceased or living individuals.

This raises questions about:

Posthumous privacy.

Digital personality rights.

Consent to AI-based impersonation.

Commercial exploitation of digital likeness.

Ownership and licensing of digital replicas.

Psychological and financial harm to surviving family members.

D. Neural preservation and brain-computer technologies

These technologies involve neural recording, brain-computer interfaces, neuroprosthetics and experimental research into preserving or interpreting neural information.

The central legal issue is whether neural information should receive special protection because of its relationship with consciousness, cognition and personal identity.

3. Legal and Regulatory Framework in India

India does not have a single statute specifically governing digital immortality. Instead, the relevant technologies are regulated through multiple overlapping legal instruments.

A. Constitutional framework

Article 21 – Right to Life and Personal Liberty

Article 21 provides the constitutional foundation for regulating human longevity technologies.

Its application includes:

Bodily autonomy and personal liberty.

Informed medical consent.

Protection against unsafe medical experimentation.

Privacy of genetic and biological information.

Human dignity and individual identity.

Protection against coercive medical interventions.

The right to life does not automatically create a right to scientifically unproven immortality or an enforceable right to access experimental life-extension technologies.

Article 14 – Equality before Law

Longevity biotechnology could create inequalities if expensive anti-ageing treatments become accessible only to wealthy individuals.

Article 14 becomes relevant where public authorities create arbitrary distinctions in access, research permissions or healthcare regulation.

Article 19(1)(g) – Freedom of Profession and Business

Biotechnology companies, research institutions and medical enterprises may rely on this provision to conduct lawful scientific and commercial activities, subject to reasonable restrictions under Article 19(6).

B. Important Indian legislation

C. Biotechnology and biosafety regulation

The Environment (Protection) Act, 1986 and the 1989 Rules establish India's biosafety regulatory framework for genetically engineered organisms and related activities.

Important regulatory institutions include:

Recombinant DNA Advisory Committee (RDAC).

Institutional Biosafety Committees (IBSCs).

Review Committee on Genetic Manipulation (RCGM).

Genetic Engineering Appraisal Committee (GEAC).

These institutions have different advisory, monitoring and approval responsibilities. Their precise jurisdiction depends on the particular biological material, research activity and regulatory classification.

The Department of Biotechnology has also issued the Regulations and Guidelines for Recombinant DNA Research and Biocontainment, 2017.

ibkp.dbt.gov.in+2

D. Gene therapy and clinical trials

The National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, provide an important framework for the development and clinical investigation of gene therapy products.

The New Drugs and Clinical Trials Rules, 2019 provide the regulatory structure for applicable clinical investigations and investigational products.

The Central Drugs Standard Control Organisation (CDSCO) plays a significant role in regulating cell and gene therapy products.

Press Information Bureau+1

A company cannot lawfully avoid clinical-trial and product-safety requirements merely by describing an experimental anti-ageing intervention as a wellness treatment or an immortality programme.

4. Detailed Legal Issues

A. Human genetic modification and the right to biological identity

Genetic modification creates a fundamental question: how far can scientific institutions alter the biological characteristics of a human being?

The legal distinction is between:

Somatic gene editing: Modification of non-reproductive cells, generally affecting the treated individual rather than future generations.

Germline gene editing: Modification of reproductive cells or embryos in ways that may transmit genetic changes to future generations.

Germline modification intended to produce permanent longevity could create serious legal problems involving:

Consent of future generations.

Unpredictable genetic consequences.

Hereditary disease risks.

Human dignity.

Genetic discrimination.

Inequality between genetically enhanced and unenhanced populations.

A regulatory system should require rigorous scientific review, ethical approval, transparent risk assessment and legally authorised research.

B. Ownership of genetic material and biological identity

An individual may provide blood, tissue, DNA or cellular material to a biotechnology company.

However, the transfer of a physical sample does not automatically settle every legal question concerning ownership, privacy, commercial use or subsequent research.

Important issues include:

Whether the original consent covers future research.

Whether the company can commercialise discoveries derived from the sample.

Whether genetic information can be shared with third parties.

Whether samples can be retained after death.

Whether relatives can be affected by the disclosure of hereditary information.

The distinction between ownership of a physical specimen, rights in personal information and intellectual-property rights in an invention is essential.

C. Cryopreservation and posthumous biological autonomy

Cryopreservation creates a legal relationship between the individual, family members, preservation companies and institutions responsible for maintaining biological materials.

The regulatory framework should address:

Advance directives.

Validity of preservation contracts.

Proof of consent.

Financial arrangements for long-term storage.

Minimum preservation standards.

Institutional insolvency.

Transfer of preserved materials.

Negligence and contractual remedies.

A preservation provider should not represent the possibility of future revival as an established medical outcome.

D. Digital resurrection and posthumous personality rights

Suppose a biotechnology company combines a deceased person's genetic information, recorded speech, photographs and AI-generated behavioural models to create a digital replica.

Several independent legal interests may arise:

A digital replica should not automatically be treated as the deceased person or as a separate legal person.

E. Liability for experimental immortality treatments

Suppose a biotechnology company advertises a genetic treatment that allegedly reverses ageing. A customer undergoes the treatment and suffers serious organ damage.

Potential liability may arise under several legal principles:

Medical negligence.

Product liability.

Deficiency in services.

Misrepresentation and fraudulent advertising.

Breach of informed-consent requirements.

Clinical-trial violations.

Institutional and professional misconduct.

Liability should be assessed according to the role of each participant: manufacturer, treating doctor, research institution, clinical investigator, sponsor and distributor.

F. Genetic discrimination and social inequality

If genetic technologies eventually permit substantial differences in longevity, society may face discrimination based on biological characteristics.

For example:

Employers might favour individuals with commercially available longevity treatments.

Insurance companies might use genetic predictions in risk assessment.

Governments might allocate healthcare resources according to predicted lifespan.

Wealthy individuals might obtain substantially longer healthy lifespans than economically disadvantaged groups.

A sound regulatory framework must protect equality, confidentiality and fair access to healthcare.

5. Important Case Laws and Their Legal Significance

There is no reported judgment establishing a general legal right to biological or digital immortality. Nevertheless, several decisions provide the foundational principles.

1. Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1

Foundational constitutional authority

Court: Supreme Court of India.

Legal issue: Whether privacy is a constitutionally protected fundamental right.

Judgment: The Supreme Court recognised privacy as a fundamental right under Article 21 and other freedoms guaranteed by Part III of the Constitution.

Relevance to digital immortality:

The judgment provides an important constitutional basis for protecting:

Genetic information.

Biological identity.

Medical records.

Neural information.

Personal behavioural data.

Digital representations of individuals.

A biotechnology company cannot assume that a person's genetic information is freely available for unrestricted commercial exploitation merely because the information has been collected.

Legal principle: Informational privacy and decisional autonomy are central to the constitutional protection of human identity.

PRIVACY+1

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Court: Supreme Court of India.

Legal issue: Validity of medical consent and the limits of a doctor's authority to undertake medical procedures.

Judgment: The Court explained that medical consent must be voluntary and based on adequate information concerning the proposed treatment.

Relevance:

A person participating in experimental longevity treatment must receive meaningful information concerning:

Scientific uncertainty.

Possible complications.

Alternative treatments.

Long-term risks.

Experimental status.

Possibility of treatment failure.

A general signature on a consent form should not automatically legitimise every experimental intervention.

Legal principle: Informed consent is an essential element of lawful medical treatment.

3. Common Cause v. Union of India (2018) 5 SCC 1

Court: Supreme Court of India.

Legal issue: Passive euthanasia and advance medical directives.

Judgment: The Supreme Court recognised the validity of advance directives and laid down a framework concerning withdrawal of life-sustaining treatment in specified circumstances.

Relevance:

The decision is important for cryopreservation and longevity regulation because it demonstrates the legal significance of previously expressed medical choices.

It raises questions about:

Advance consent for preservation.

Medical decision-making when a person loses capacity.

Refusal of medical intervention.

End-of-life autonomy.

Conflicts between personal wishes and family preferences.

However, the judgment does not itself establish a right to cryonic preservation or future revival.

4. Yash Charitable Trust v. Union of India 2026 INSC 96

Highly relevant biotechnology authority

Court: Supreme Court of India, 30 January 2026.

Legal issue: Regulation of stem-cell interventions, particularly interventions offered for autism spectrum disorder.

Judgment: The Court examined whether patient consent alone could justify offering an unapproved or unproven stem-cell intervention as a medical treatment.

The Court considered the principles in Samira Kohli and emphasised that informed consent does not independently establish the legality or scientific acceptability of an otherwise impermissible treatment.

Relevance to digital immortality biotechnology:

This decision is particularly significant for commercial longevity clinics.

A company cannot establish the legality of an unapproved anti-ageing intervention simply by obtaining a signed declaration from a customer.

The regulatory framework must independently consider:

Scientific evidence.

Clinical safety.

Approved indications.

Professional standards.

Applicable regulatory permissions.

The Ministry of Health subsequently reiterated that stem-cell therapy should be offered as standard care only for approved indications.

Sci API+2

5. Re JS (Disposal of Body) [2016] EWHC 2859 (Fam)

Court: Family Division, High Court of England and Wales.

Facts: A 14-year-old girl suffering from terminal cancer wanted her body to be cryonically preserved after death. Her parents disagreed about the arrangements.

Judgment: The court permitted the mother to make the necessary arrangements for the preservation of the girl's body.

Legal significance:

The case directly illustrates the legal problems associated with cryonics:

Autonomy of a minor with decision-making capacity.

Parental disagreement.

Control over disposal of a deceased person's body.

Practical arrangements for preservation.

Financial and logistical responsibility.

The decision did not establish that cryonics is medically effective or create a general right to be cryopreserved.

Legal principle: The court's decision concerning disposal of a body may depend on the particular circumstances, the wishes of the deceased and the applicable law.

Bailii+2

6. Moore v. Regents of the University of California 793 P.2d 479 (Cal. 1990)

Court: Supreme Court of California, United States.

Facts: John Moore's cells were used in developing a commercially valuable cell line without his knowledge of the research and commercial interests involved.

Judgment: The court rejected Moore's conversion claim based on ownership of the excised cells but allowed other claims, including potential failure to disclose conflicts of interest.

Relevance:

The case is particularly important for commercial longevity research.

It illustrates the distinction between:

Ownership of removed biological material.

Disclosure obligations.

Research interests.

Commercial intellectual property.

Patient autonomy.

A company developing a profitable anti-ageing product using donated human cells must consider consent, disclosure and applicable research requirements.

7. Association for Molecular Pathology v. Myriad Genetics 569 U.S. 576 (2013)

Court: Supreme Court of the United States.

Legal issue: Patentability of naturally occurring human DNA.

Judgment: Naturally occurring DNA segments do not become patentable merely because they have been isolated. Synthetically created cDNA may be patent eligible in the circumstances considered by the Court.

Relevance:

The decision is important for biotechnology businesses seeking patents over:

Genetic sequences.

Longevity-related genes.

Biological discoveries.

Artificially engineered genetic materials.

Gene-editing technologies.

It demonstrates that discovering naturally occurring biological information is legally different from creating a patent-eligible invention.

8. Brüstle v. Greenpeace eV Case C-34/10 (2011)

Court: Court of Justice of the European Union.

Legal issue: Patentability of inventions involving human embryonic stem cells.

Judgment: The Court interpreted the EU biotechnology patent framework and restricted patentability for inventions involving uses of human embryos for industrial or commercial purposes within the applicable legal definition.

Relevance:

This case provides guidance on the ethical limits of commercialising embryo-related biotechnology.

It is relevant to technologies involving:

Embryonic stem cells.

Regenerative medicine.

Embryo preservation.

Genetic modification.

Commercial biological research.

It also demonstrates that scientific innovation and patent rights may be restricted by human dignity and public-order considerations.

6. International Legal Framework

A. UNESCO and human genome governance

The UNESCO Universal Declaration on the Human Genome and Human Rights, 1997, establishes important ethical principles concerning human genetic research.

Its underlying principles include:

Respect for human dignity.

Protection against genetic discrimination.

Informed consent.

Responsible scientific research.

Protection of genetic confidentiality.

International cooperation.

The Declaration is relevant to technologies that seek to alter the biological characteristics of human beings to extend lifespan.

B. European biotechnology regulation

The European regulatory framework includes:

EU Directive 98/44/EC on the legal protection of biotechnological inventions.

General Data Protection Regulation (GDPR).

EU Clinical Trials Regulation.

EU Regulation 2017/746 on in-vitro diagnostic medical devices, where applicable.

Convention on Human Rights and Biomedicine (Oviedo Convention), for its contracting states.

These instruments address biotechnology patents, personal information, clinical research and human dignity.

C. International bioethics and human experimentation

The Declaration of Helsinki and CIOMS International Ethical Guidelines provide influential ethical standards for medical research involving human participants.

They are relevant to experimental longevity interventions, especially where participants are exposed to uncertain or irreversible biological risks.

7. Additional Doctrinal Principles

The following principles can form the theoretical foundation of a Digital Immortality Biotechnology Regulation Doctrine.

These are proposed analytical doctrines, not independently established legal causes of action.

8. Regulatory Accountability of Biotechnology Companies

A comprehensive regulatory framework should impose responsibilities on different categories of institutions.

Corporate liability

A biotechnology organisation may face legal consequences where it:

Provides an unapproved treatment contrary to applicable law.

Conceals material scientific risks.

Uses genetic material beyond the authorised scope.

Falsifies clinical research results.

Misrepresents the probability of biological revival.

Negligently damages preserved biological materials.

Improperly discloses genetic or medical information.

Creates deceptive digital replicas of deceased individuals.

Corporate responsibility should not be avoided through contractual clauses stating that the customer accepts every possible risk.

9. Proposed Regulatory Model for India

A specialised regulatory framework could be developed through the following institutional structure.

Proposed Digital Immortality Biotechnology Regulatory Architecture

National Digital Immortality and Biotechnology Regulatory Authority

Proposed coordinating institution; not an existing Indian authority

Genetic Research Division

Gene editing and biological modification

Longevity Medicine Division

Clinical trials and regenerative therapies

Cryogenic Oversight Division

Preservation and custodial standards

Digital Identity Division

AI replicas and posthumous data

Ethics and Consent Division

Autonomy and research ethics

Liability and Enforcement Division

Compensation and compliance

Proposed architecture integrating existing regulatory responsibilities rather than replacing CDSCO, DBT, ICMR or other statutory authorities.

Recommended legislative provisions

A future Indian statute or coordinated regulatory framework should address the following:

Section 1 – Definitions: Define biological longevity, digital immortality, genetic preservation, cryonics, neural data and digital personality reconstruction.

Section 2 – Licensing: Require appropriate regulatory permissions for covered biotechnology activities.

Section 3 – Informed consent: Establish specific consent standards for experimental longevity procedures and biological preservation.

Section 4 – Genetic safeguards: Regulate high-risk genetic modifications and inheritable interventions.

Section 5 – Biological material custody: Establish preservation, transfer, record-keeping and insolvency procedures.

Section 6 – Digital personality protection: Regulate the commercial and deceptive use of digital replicas.

Section 7 – Data protection: Require lawful processing and appropriate safeguards for genetic, medical and neural information.

Section 8 – Research accountability: Mandate independent ethical review, research transparency and adverse-event reporting.

Section 9 – Compensation: Provide remedies for negligence, unlawful experimentation and defective products.

Section 10 – Intergenerational safeguards: Establish restrictions and review mechanisms for interventions capable of producing heritable consequences.

Section 11 – Consumer protection: Prohibit deceptive claims concerning guaranteed immortality, biological reversal or future revival.

Section 12 – International cooperation: Facilitate cross-border cooperation concerning preserved biological material, genetic research and digital identity.

10. Major Unresolved Legal Questions

Digital immortality biotechnology creates several questions that existing legal systems have not conclusively answered.

A. Can biological immortality become a fundamental right?

Article 21 protects life and personal liberty, but it does not presently guarantee unlimited biological existence.

The constitutional challenge is to distinguish between:

A right to receive lawful medical treatment.

A right to refuse medical intervention.

A right to participate in properly regulated research.

An alleged right to access technologies that promise indefinite life.

The first three have established legal foundations. The fourth remains speculative and legally unsettled.

B. Does a digital reconstruction possess legal personality?

An AI system trained on a deceased person's memories, voice and genetic information does not automatically acquire the legal personality of that person.

Legal recognition would require separate legislative consideration of identity, agency, responsibility and the interests of living persons.

C. Can future generations challenge genetic modifications?

Where a genetic intervention creates inheritable consequences, future individuals may suffer harms without having participated in the original decision.

This creates a difficult question concerning intergenerational responsibility and the limits of parental and scientific decision-making.

D. Who is responsible for failed biological preservation?

Where a company promises long-term preservation but subsequently becomes insolvent or negligently damages the biological material, questions arise concerning contractual liability, negligence, consumer protection and custodial obligations.

The law must distinguish a contractual promise to preserve material from an unsupported promise to restore life.

11. Comparative Case Law Summary

12. Critical Academic Analysis

From a jurisprudential perspective, digital immortality biotechnology challenges the traditional legal understanding of the relationship between human existence and legal identity.

Traditional legal systems generally associate legal personality with a living human being or a legally recognised organisation. Digital immortality technologies challenge this assumption by separating biological existence, genetic continuity, memory preservation and computational representation.

Three fundamental distinctions are necessary.

First: Biological continuity is not necessarily personal continuity.

Preserving a person's cells or genetic information does not establish that their consciousness or personal identity has survived.

Second: Digital continuity is not necessarily legal continuity.

An AI reconstruction may imitate a deceased individual's communication patterns without becoming the original individual.

Third: Scientific possibility is not equivalent to legal entitlement.

Even if future technologies achieve substantial extensions of human lifespan, their development and distribution must remain consistent with medical safety, equality, dignity and applicable legal standards.

The central jurisprudential challenge is therefore to prevent technological progress from eliminating the legal distinction between a human being, biological material and an artificial representation.

13. Conclusion

Digital Immortality Biotechnology Regulation represents an emerging intersection of constitutional law, biotechnology law, medical jurisprudence, genetic privacy, AI governance and human-rights protection.

For India, the constitutional principles in Puttaswamy, the informed-consent standards in Samira Kohli, the advance-directive framework in Common Cause, and the Supreme Court's 2026 decision in Yash Charitable Trust provide important foundations.

The international decisions in Re JS, Moore, Myriad Genetics and Brüstle provide additional guidance concerning cryopreservation, biological ownership, genetic patents and embryo-related research.

Ultimately, the purpose of biotechnology regulation should not be to prohibit scientific attempts to extend healthy human life. It should be to ensure that scientific ambitions do not override human autonomy, biological integrity, dignity, accountability and the rights of future generations.

The fundamental principle of this proposed doctrine is that the preservation, modification or digital reconstruction of human identity must remain legally accountable, scientifically defensible and ethically governed.

Academic qualification: This is a developing interdisciplinary legal framework, not a recognised standalone branch of enacted Indian law. The cases discussed provide analogous legal principles rather than direct judicial recognition of a right to digital or biological immortality.